propionanilide] is a potent opioid analgesic agent, but a has narrow therapeutic index. We reported earlier on the synthesis and bioefficacy of fentanyl and its 1-substituted analogs (1-4) in mice. Here we report the synthesis and biological evaluation of four additional analogs, viz. N-isopropyl-3-(4-(N-phenylpropionamido)
Introduction
Severe and chronic pain conditions are usually alleviated by narcotic (opioid) analgesics like morphine (Vogel, 2002) . However, their beneficial effects are often obscured by unwanted effects like constipation, nausea, vomiting, etc. (Kalso et al., 2004) . Fentanyl [N-(1-phenethyl-4-piperidinyl) propionanilide] is a fully synthetic opioid analgesic that has found several clinical applications because of its rapid onset of action and good safety margin. As an analgesic, it is several times more potent than morphine (Mather, 1983; Mićović et al., 2000 ; Van death (Gardocki & Yelnosky, 1964) . In order to discover an analgesic with improved pharmacodynamics and pharmacokinetics, extensive efforts have been made in synthesizing several new fentanyl analogs and determining their structure activity relationship (SAR) (Casy and Parfitt, 1986; Bagley et al., 1991; Portoghese, 1992; Bi-Yi et al., 1999; Gerak et al., 1999) . Such studies can lead to an ideal analgesic with greater potency, duration of action and safety (Higashikawa & Suzuki, 2008) .
We also reported on the synthesis and bioefficacy of fentanyl and its 1-substituted analogs (1-4), where the phenethyl chain of fentanyl was replaced by alkyl, ethereal and nitrile functional groups (Gupta et al., 2013) . Compared to fentanyl and its four analogs, 2 exhibited the lowest median effective dose (ED 50 ) and highest potency ratio. Therefore, with an objective to synthesize more compounds with still lower ED 50 and higher potency ratio, we report here the synthesis and biological evaluation of four more 1-substituted analogs of fentanyl, viz., N-isopropyl-3-(4-(N-phenylpropionamido) piperidin-1-yl)propanamide (5), piperidin-1-yl)propanamide (6), isopropyl 2-[4-(N-phenylpropionamido)piperidin-1-yl] propionate (7) and t-butyl 2-[4-(N-phenylpropionamido) piperidin-1-yl]propionate (8). In the present study, the phenethyl chain of fentanyl was replaced by different functional groups, viz. N-isopropyl propanamide, N-tbutyl propanamide, isopropyl propionate, and t-butyl propionate moieties. The median lethal dose (LD 50 ), opioid receptor-mediated activity, antinociceptive effects, ED 50 , and analgesic potency ratio of 5-8 were determined and compared with fentanyl as reported earlier in our publication (Gupta et al., 2013) .
Materials and methods

Chemistry
All the chemicals used in the present study were of the highest purity. Acrylonitrile (CAS 107-13-1), 2-bromopropionyl chloride , dimethyl sulfoxide (DMSO; CAS 67-68-5) and naloxone hydrochloride (CAS 51481-60-8) were purchased from Sigma-Aldrich Inc. (St. Louis, USA). Formaldehyde (CAS: 50-00-0) was procured from Merck (Mumbai, India), isopropanol was obtained from Rankem (New Delhi, India), and tertbutanol (CAS 75-65-0) was from Acros (NJ, USA).
Synthesis of fentanyl analogs
All the 1-substituted fentanyl analogs were synthesized from a common precursor (N-(4-piperidinyl)propionanilide), prepared by the procedure reported earlier (Gupta et al., 2013) , and they were found to be >98% pure. Structure and yield of fentanyl analogs are shown in Table 1 . To a mixture of N-benzyl-4-piperidone (0.10 moles), aniline (0.10 moles) and activated zinc (0.40 moles), 90% aqueous acetic acid (1.60 moles) was added portion wise, -isopropyl-3-(4-(N-phenylpropionamido)piperidin-1-yl) propanamide -CH 2 CH 2 NHPr i 345 60 -t-butyl-3-(4-(N-phenylpropionamido) 3440, 3250, 3025, 2930, 2848, 1605, 1526, 1492, 1371, 1317, 1250, 1085, 975, 862, 750, 690 , 8.13; N, 8.69. Found: C, 78.15; H, 8.00; N, propionanilide (BPP; 3) To the solution of ANBP (0.08 moles), 150 ml of 1,2-dichloroethane, propionyl chloride (0.24 moles) was added drop-wise and the resulting mixture was stirred at ambient temperature for 2 h. After completion of the reaction, the reaction mixture was poured slowly into 4% aqueous sodium hydroxide solution with continuous stirring. The resulting alkaline solution was extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulphate and concentrated under reduced pressure to get the crude product. 265, 173, 158, 146, 132, 118, 91, 82, 77, 65, 57; Anal. Calcd. for C 21 H 26 N 2 O: C, 78.22; H, 8.13; N, 8.69. Found: C, 78.15; H, 8.00; N, propionanilide (PP; 4) A solution of BPP (0.07 moles) in 125 ml methanol-acetic acid mixture (3:2) was taken in a 250 ml thick-walled hydrogenation vessel containing 10% palladium on charcoal catalyst (10% w/w). The hydrogen gas was then purged into the vessel using Parr apparatus at 50 °C. When no further amount of hydrogen was consumed, the vessel was removed and the contents were filtered through celite. 175, 146, 132, 118, 82, 77, 68, 57, 55; Anal. Calcd. for C 14 H 20 N 2 O: C, 72.38; H, 8.68; N, 12.06. Found: C, 72.05; H, 8.50; N, 11.99 .
4-Anilino-N-benzylpiperidine (ANBP;
2N N O R 6 N
Synthesis of 5 and 6
In a three neck round bottom flask, sulfuric acid (150 mmol) was heated to 45 °C and a mixture of acrylonitrile (75 mmol) and isopropanol/tert-butanol (74 mmol) was added drop-wise. Thereafter, the reaction mixture was stirred at 60 °C for 3 h to complete the reaction. The reaction mixture was then poured cautiously into ice cooled water with continuous stirring. The white precipitate was filtered off, washed well with plenty of water and dried under vacuum to obtain N-isopropyl/ tert-butyl acrylamide. To a solution of N-isopropyl or t-butyl acrylamide (10 mmol) and N-(4-piperidinyl)propionanilide (10 mmol) in acetonitrile, silica gel (1.0 g) was added and the heterogeneous mixture was stirred at 80 °C till completion of the reaction. The reaction mixture was filtered, concentrated under vacuum and purified by flash chromatography to give the desired compounds (5 and 6).
Bioassay of fentanyl analogs
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N-isopropyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (5)
11 12 Colorless solid (60%); mp 108-110 °C. IR (KBr) max 3327, 3235, 2941, 2822, 1657, 1626, 1460, 1448, 1264, 1283, 1123, 867, 643 345, 316, 288, 245, 231, 189, 175, 159, 146, 132, 120, 93, 82, 68, 55, 44, 29 
N-t-Butyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (6)
11 12 Colorless solid (65%); mp 92-95 °C. IR (KBr) ν max 3327, 3235, 3063, 2963, 2948, 2888, 1657, 1627, 1561, 1433, 1268, 1261, 1174, 837 360, 340, 330, 302, 286, 259, 245, 231, 209, 189, 175, 159, 146, 132, 118, 96, 82, 57, 42, 29; Anal. Calcd. for C 21 H 33 N 3 O 2 : C, 70.12; H, 9.18; N, 11.58. Found: C, 70.16; H, 9.25; N, 11.69 .
Synthesis of 7 and 8
To a solution of Isopropanol/tert-butanol (38 mmol) in toluene (25 ml), 2-bromopropionyl chloride (38 mmol) was added drop-wise and the reaction mixture was stirred at room temperature for 4 h under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate and concentrated under reduced pressure to get the desired ester as oils. Thereafter, to a solution of isopropyl or t-butyl 2-bromopropionate (10 mmol) and N-(4-piperidinyl)propionanilide (10 mmol) in DMF-water, potassium carbonate was added and the reaction mixture was stirred at 80 °C. When the reaction was complete, the reaction mixture was filtered, and the filtrate was diluted with water and extracted with ethyl acetate. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate; the combined organic phase was washed with brine, dried over sodium sulfate and concentrated under vacuum to give the crude product which was purified by flash chromatography to give the desired compounds (7 and 8). 346, 331, 317, 289, 259, 216, 203, 187, 146, 132, 110, 93, 82, 56; Anal. Calcd. for C 20 
Isopropyl 2-[4-(N-phenylpropionamido)piperidin-1-yl]propionate (7)
Determination of LD 50
The LD 50 of the compounds was determined by intravenous (i.v.), intraperitoneal (i.p.) and oral (p.o.) routes following Dixon's up and down method (Dixon, 1965) , using 4-6 mice for each value. All the compounds were dissolved in DMSO and administered in a volume <10 ml/kg body weight. To determine the i.v. LD 50 , the compounds were administered through the tail vein using a 27 gauge needle, and for the p.o. LD 50 , a 16 gauge oral feeding cannula (HSE-Harvard, Germany) was used. Although, the animals were observed for 14 days, the mortality invariably occurred within the first 24 h. All the dead animals were autopsied to see any visceral changes. All the observations were compared with those of fentanyl (Gupta et al., 2013) .
Observational assessment
Observational assessment on spontaneous activities of the CNS, peripheral nervous system (PNS) and autonomic nervous system (ANS) was performed as per the modified method discussed elsewhere (Irwin, 1964 (Irwin, , 1968 (Gupta et al., 2013) .
Determination of opioid antagonist activity
To confirm the opioid receptor-mediated effects of the compounds, mice were treated with 0.50 LD 50 (i.p.) of the analogs (5-8), in the presence or absence of naloxone hydrochloride (5.0 or 10.0 mg/kg; s.c.; -10 min). Soon after, the animals were closely observed for various neurotoxic manifestations of the compounds and their disappearance in the presence of naloxone hydrochloride (Matosiuk et al., 2002; Leavitt, 2009) . Three animals were used for each treatment.
Determination of ED 50 , potency ratio and therapeutic index
Analgesic ED 50 of all the compounds was determined by formalin-induced hind paw licking method (Hunskar & Hole, 1987 (Gupta et al., 2013) .
Measurement of analgesic activity
Analgesic activity of the analogs was assessed at their ED 50 by formalin-induced hind paw licking test (Hunskar & Hole, 1987) and tail immersion test (Janssen et al., 1963) . To perform the hind paw licking test, mice were divided into six groups of six animals each and given various treatments (i.p.) as follows: (i) vehicle control (DMSO), (ii) fentanyl (28.0 μg/kg, (iii) 5 (20.5 μg/kg), (iv) 6 (21.0 μg/kg), (v) 7 (35.5 μg/kg), and (vi) 8 (55.0 μg/kg). Thirty minutes after administration of different compounds, formalin (2.5%, 20 μl) was injected sub-plantarly in one hind paw. The duration of paw licking as index of nociception was monitored at 0-5 min (neurogenic phase) and 15-30 min (inflammatory phase). To conduct the tail immersion test, mice received various treatments as discussed above. The distal part (2-3 cm) of the tail was immersed in hot water maintained at 55.0±1.0 °C, and the time taken by the mice to deflect or withdraw the tail was recorded as the reaction time. A cut off time of tail immersion was taken as 10 sec, and thereafter the measurement was stopped to avoid any tissue injury. The initial reading was taken immediately before treatment and then at 15, 30, 45, and 60 min post treatment. Tail withdrawal in vehicle treated mice usually occurs between 2.6 and 3.0 sec. Therefore, a withdrawal time of >3 sec was considered as a positive response. Prior to the analgesic test, the animals were screened by immersing their tail in hot water (55.0±1.0 °C) and only those animals were selected for the experiment which showed tail withdrawal latency of <5 sec.
Statistics
Results of analgesic activity were expressed as mean ± SE (n=6). The statistical analysis was carried out by Student's t test, using SigmaStat software (SSP Inc., USA). Statistical significance was drawn at p<0.05 and p<0.01. Fentanyl analogs, viz., 5-8 were administered through different routes and acute (24 h) LD 50 was determined by Dixon's up and down method (Dixon, 1965) . Values in parentheses are fiducial limits at 95% confidence interval. Immediately after treatment, the animals were closely observed for 2 h by a blind observer for its effects on CNS, PNS (effects after manipulation and effects on reflexes) and ANS activities. The scorings were given as: 0 (no observational change), + (little activity), ++ (moderate flexibility), +++ (strong response) and ++++ (exaggerated response). Each treatment included three animals. manipulations) included auditory stimulus response, escape after touch, righting reflex, paresis of hind limbs, paresis of forepaws, and catalepsy in induced positions, while PNS activities (reflexes) included pinna reflex, corneal reflex, and pain following stimulation. The ANS activities included eyelids (closure or exophthalmus), salivation, lacrimation, cyanosis, piloerection, defecation and urination. All the compounds administered through i.v. (Table 3 ) and i.p. (Table 4 ) routes exhibited more intense activities compared to p.o. (Table 5) route. Also, all the compounds showed severe effects on CNS and PNS activities compared to ANS by all the routes of administration. Manifestations like defecation and micturation were only minimal. After p.o. administration, 5, 6 and 7 showed little CNS activity at low dose, but 8 did not show any response whatsoever. Also, all the analogs except 7 did not show any PNS activity (reflexes) at low and medium doses. After i.p. administration, none of the analogs revealed any PNS activity (reflexes) at low dose, while after i.v. administration all the analogs exhibited CNS and PNS activities at low dose, with the exception of 7, which did not result in any PNS activity. In general, all the analogs exerted effects on CNS, PNS and ANS activities practically comparable to those induced by fentanyl.
Results
Toxicity of fentanyl analogs
Determination of opioid antagonist activity
In the present study, pre-treatment of 5 mg/kg naloxone was found to quickly reverse the neurotoxic effects produced by 0.50 LD 50 (i.p.) of 5 and 6, while the same dose of naloxone could not reverse the neurotoxic effects of 7 and 8, for which a higher dose of 10 mg/kg was required. Table 6 summarizes the results on analgesic ED 50 , potency ratio and therapeutic index of fentanyl analogs, determined by formalin-induced hind paw licking method. The ED 50 (μg/kg) of 5 (20.5) and 6 (21.0) was less, and that of 7 (35.5) and 8 (55.0) was more than that of fentanyl (28.0). Conversely, the potency ratio of 5 (1.37) and 6 (1.33) was more, and that of 7 (0.79) and 8 (0.51) was less than that of fentanyl (1.0). The therapeutic index was in the following order: 7 (7828.2) >8 (6361.8) >5 (5551.2) >6 (5109.5) >fentanyl (625.0). In brief, the lowest ED 50 and the highest potency ratio were observed in the case of 5, followed by 6. However, the maximum therapeutic index was exhibited by 7, compared to the lowest observed in case of fentanyl. This indicates that all the compounds were 8-12 times safer than fentanyl. Figure 1 shows the analgesic activity of fentanyl and its analogs measured at their respective ED 50 , determined by Table 5 . Observational assessment after oral administration of fentanyl analogs in mice. Immediately after treatment, the animals were closely observed for 2 h by a blind observer for its effects on CNS, PNS (effects after manipulation and effects on reflexes) and ANS activities. The scorings were given as: 0 (no observational change), + (little activity), ++ (moderate flexibility), +++ (strong response) and ++++ (exaggerated response). Each treatment included three animals. Analgesic ED 50 of fentanyl analogs, viz., 5-8 was determined by formalininduced hind paw licking method (Hunskar & Hole, 1987; Litchfield & Wilcoxon, 1949) . The potency ratio was determined as the ratio of ED 50 of fentanyl 28.0 (μg/kg) (Gupta et al., 2013) and ED 50 of each analog. The therapeutic index was calculated as the ratio of LD 50 of the compounds and their ED 50 . Values in parentheses are fiducial limits at 95% confidence interval. formalin-induced hind paw licking method. The duration of paw licking as index of nociception was observed at the first phase (0-5 min) and second phase (15-30 min).
Determination of ED 50 , potency ratio and therapeutic index
Measurement of analgesic activity
Comp. Dose CNS PNS
ANS
After manipulations Reflexes
Control
In the first phase, none of the compounds displayed any analgesic activity because the time spent in paw licking did not decrease compared to control. However, in the second phase, all the compounds exhibited significant (p<0.01) analgesic activity compared to control. Further, compared to control, the percentage of decrease in time of paw licking was 78.5, 68.8, 69.2, 44.3, and 49 .9 for fentanyl, 5, 6, 7, and 8, respectively. The data show that in the second phase, antinociceptive activity of 7 and 8 was lower than that of other compounds. Figure 2 refers to the analgesic activity of fentanyl and its analogs measured by tail immersion method. Animals receiving ED 50 of the compounds were observed to increase the reaction time after thermal stimuli given at different time points after treatment. All the values were compared to control at the corresponding time point. Fentanyl showed significant (p<0.01) analgesic activity at 15, 30 and 45 min posttreatment, the maximum being at 30 min. The analgesic activity of 5 and 6 was evident at all the time points. The analgesic activity of 5 progressively increased after 15 min to a maximum at 45 min, thereafter it declined at 60 min. On the other hand, analgesic activity of 6 was maximum at 15 min, which gradually declined by 60 min. However, at this time also both 5 and 6 were significantly (p<0.05) different from the corresponding control. Compound 7 and 8 displayed significant analgesic activity at 15 and 30 min only, the maximum for both being observed at 30 min. In brief, both 5 and 6 demonstrated longer antinociceptive activity compared to fentanyl, while the effects of 7 and 8 were short-lived.
Discussion
Although fentanyl is widely used as a narcotic analgesic agent, it has been implicated in drug abuse and fatalities due to overdosing and narrow therapeutic window (Yassen et al., 2008; Jumbelic, 2010) . Over many recent years, SAR and molecular modeling of several new analogs of fentanyl have projected many potent compounds (Vučković et al., 2000) . Our recent work also revealed some effective 1-substituted analogues of fentanyl (Gupta et al., 2013) . The present study reports the synthesis, and biological evaluation of four new fentanyl analogs. The LD 50 of the new analogs by different routes revealed that all the compounds were less toxic compared to fentanyl, thus showing an improved margin of safety over fentanyl. Autopsy of the animals succumbing to high doses of the compounds showed severe intestinal hemorrhage. This possibly occurred due to pooling of blood following hypovolemic shock. Similar observations were also made during our previous study (Gupta et al., 2013) and after administration of methyl-substituted and para-substituted fentanyl analogs (Higashikawa & Suzuki, 2008) . Observational assessment on spontaneous CNS, PNS, and ANS activities is usually performed to evaluate the psychotropic activity and toxicity of the compounds (Irwin, 1964 (Irwin, , 1968 . Observational assessment made in the present study revealed that all the compounds exerted significant dose-dependent influence on CNS and PNS activities. Also, the compounds were found to induce straub's phenomenon, catalepsy, rigidity, circling and stereotypical behavior, which are distinctive characteristics of opioid analgesics. Severe convulsions, a typical attribute of morphine intoxication, were also observed. This can be attributed to inhibition of release of gamma-aminobutyric acid by interneurons (McGinty & Friedman, 1988) . All the compounds were evaluated through parenteral and p.o. routes of administration, which are the preferred routes of opioids for pain management (Gardocki & Yelnosky, 1964; Hallenbeck, 2003; Vučkovic et al., 2011) . In the present study, most of the observations on motor coordination and behavioral tests of fentanyl analogs were very similar to previous observations with fentanyl (Gardocki & Yelnosky, 1964) . There were also reduced ANS activities, like defecation and micturation, which are typical of opioid analgesics (Gupta et al., 2013) . Short acting opioid antagonists, such as naloxone, have been successfully used to rapidly reverse the neurotoxic effects of opioid overdose (Leavitt, 2009) . Naloxone is a nonselective antagonist of opioid receptors, and is generally used to verify any opioid-mediated effects of the drugs Jagerovic et al., 2002) . In the present study, pre-treatment of naloxone completely reversed the neurotoxic effects of all the analogs, confirming that their effects were possibly mediated through MOR (Mićović et al., 2000; Jagerovic et al., 2002; Leavitt, 2009) . This is in agreement with a previous study which reported that such a receptor is involved in Straub's phenomenon, muscle rigidity, catalepsy and other morphine-like behavioral effects in rats (Vučković et al., 2012) .
In the present study, the analgesic activity of 1-substituted analogs of fentanyl was determined by formalininduced hind paw licking method (Hunskar & Hole, 1987) and tail immersion test (Janssen et al., 1963) . The formalin test is a widely used model for screening novel compounds for the treatment of neuropathic pain. The method involves a behavioral nociceptive test that assesses the response of the animal to moderate and continuous pain (Meunier et al., 1998) . Formalin produces biphasic pain behavior. The first phase (i.e. neurogenic phase) is due to the direct effect of formalin on nociceptors, while the second phase (i.e. inflammatory phase) is due to the development of an inflammatory response caused by tissue injury leading to the release of histamine, serotonin, prostaglandin and excitatory amino acids (Correa & Calixto, 1993; Damas & Liegeois, 1999) . In the present study, all the analogs were found to be more effective in the second phase, which could be due to their implications as inhibitors of pain mediators during the late phase. In the present study, 5 and 6 exhibited higher potency compared to fentanyl but lower analgesic activity when evaluated at respective ED 50 . Potency and efficacy are different concepts, and when an agonist possesses high potency, it need not display also high efficacy, and vice versa (Lambert, 2004 ). An agonist capable of producing the maximum response in that system is termed a full agonist and anything that produces a lower response is a partial agonist. The ability of the agonist to bind to the receptor will determine the ability to produce a response and to some extent the size of that response (Lambert, 2004) . The tail immersion test is widely employed for opioid analgesics. This method gives intensity, onset, peak, duration of action and safety of fentanyl and other morphine like analgesics (Janssen et al., 1963) . In the present study, onset, peak and duration of the analgesic effect of all the analogs were compared with those of fentanyl by using tail immersion test. In order to perform this study, all the compounds were tested at their ED 50 . We found that 5 and 6 produced analgesia for a longer duration compared to fentanyl. Most of the opioid analgesics exert their analgesic and adverse effects primarily through MOR. However, individual strong opioids may interact, at least in part, with different opioid receptor sub-populations or modulate MOR signaling in different ways (Pasternak, 2004; Lee et al., 2007) , which may improve tolerability (Ananthan, 2006; Smith, 2008; Spetea et al., 2010) . Previous studies have shown that 4-methyl fentanyl was four times more potent than fentanyl (Mićović et al., 2000) , while introduction of 3-carbomethoxy group in the piperidine ring of fentanyl reduced the potency but did not affect the tolerability and safety (Vučkovic et al., 2011) . The shorter duration of action of 3-carbomethoxy fentanyl in comparison with fentanyl might be due to the susceptibility of the carbomethoxy group to rapid hydrolysis by non-specific esterases (Feldman et al., 1991) . It is also conceivable that the introduction of a 3-carbomethoxy group in the piperidine ring affects the duration of action by altering physicochemical properties (Scholz et al., 1996) .
Conclusion
Opioid analgesics are usually prescribed for acute and chronic pain management but their use is restricted due to undesirable side effects and a narrow therapeutic window. The present study addresses the synthesis and biological evaluation of four new 1-substituted analogs of fentanyl, where the phenethyl tail of fentanyl was replaced by different functional groups. All the compounds exhibited 8-12 fold increase in therapeutic index but only two compounds (5 and 6) produced lower ED 50 and higher potency ratio compared to fentanyl. Thus out of the four compounds tested, only two were found to be promising for further studies on pain management.
